Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rizzoli, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rizzoli, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:700-701, 2004
© 2004 European Society for Medical Oncology

Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer

René Rizzoli

Service of bone diseases, WHO Collaborating Center for Osteoporosis prevention, Department of Rehabilitation and Geriatrics, University Hospital, Geneva, Switzerland (E-mail: Rene.Rizzoli@medecine.unige.ch)

The first 10% of the full text of this article appears below.

Formerly called diphosphonates, bisphosphonates have been used as water softeners since the second half of the nineteenth century. Their role in bone and mineral metabolism was recognized about 35 years ago with the pioneering research of Herbert Fleisch in Switzerland [1, 2]. More recently, bisphosphonates have become the first choice for standard care in the management of bone diseases associated with hyper-resorption, such as Paget’s bone disease, hypercalcemia of malignancies, osteoporosis (both idiopathic and secondary), disuse, and prosthesis or implant loosening. Their consistent and large efficacy in preventing skeletal events associated with bone metastases is a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?